These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6078282)

  • 1. [Experiences with 3 patients with hemophilia A and a circulating anticoagulant].
    van Creveld S; Mochtar IA; Charante-Van der Meulen ; Pascha CN; Stibbe J
    Ned Tijdschr Geneeskd; 1967 Sep; 111(36):1555-8. PubMed ID: 6078282
    [No Abstract]   [Full Text] [Related]  

  • 2. [Studies on a circulating anticoagulant against antihemophilic factor in patients with hemophilia A].
    van Creveld S; Mochtar IA; Charante-Meulen CC
    Ned Tijdschr Geneeskd; 1967 Sep; 111(37):1589-93. PubMed ID: 5602751
    [No Abstract]   [Full Text] [Related]  

  • 3. [Autocorrection of coagulation time in Hemophilia A].
    Schneer JH; Chipail A; Mănăila T
    Rev Med Chir Soc Med Nat Iasi; 1975; 79(2):211-4. PubMed ID: 1166156
    [No Abstract]   [Full Text] [Related]  

  • 4. Circulating anticoagulant in patients with hemophilia A.
    Uszyński L; Lopaciuk S
    Pol Med J; 1969; 8(4):862-9. PubMed ID: 4105591
    [No Abstract]   [Full Text] [Related]  

  • 5. [Circulating anticoagulant in hemophilia A: laboratory evidence of a coagulation factor 8 inhibitor].
    Hule V
    Vnitr Lek; 1967 Sep; 13(9):859-65. PubMed ID: 6081657
    [No Abstract]   [Full Text] [Related]  

  • 6. Trypsin clotting time (K-test) in hemophilia A and in hemophilia B1.
    Girolami A; Dal Bo Zanon R; Procidano M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(6):863-71. PubMed ID: 6176512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired circulating anticoagulant in classical hemophilia: treatment with prothrombin concentrate.
    Rosen R; Mikel T; Corrigan JJ
    Ariz Med; 1977 May; 34(5):340-2. PubMed ID: 883905
    [No Abstract]   [Full Text] [Related]  

  • 8. [Problems posed by surgery in a hemophiliac with circulating anticoagulants. Apropos of 3 cases].
    Lareng L; Bierme R; Pris J; Bertrand JC
    Anesth Analg (Paris); 1975; 32(4):623-6. PubMed ID: 1227338
    [No Abstract]   [Full Text] [Related]  

  • 9. [Hemophilia A complicated by the presence of a circulating anticoagulant].
    Zawilska K; Owczarek L; Furmaniuk J
    Acta Haematol Pol; 1973; 4(3):265-8. PubMed ID: 4754133
    [No Abstract]   [Full Text] [Related]  

  • 10. Is hemophilia a disease of the tissue factor pathway of coagulation?
    Nemerson Y; Zur M
    Prog Clin Biol Res; 1981; 72():77-83. PubMed ID: 6801686
    [No Abstract]   [Full Text] [Related]  

  • 11. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
    Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
    Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Studies on the aggregation of blood platelets in patients with hemophilia A].
    Riech PC; Pfitzner W; Brüster H
    Z Kinderheilkd; 1968; 102(3):204-11. PubMed ID: 5710856
    [No Abstract]   [Full Text] [Related]  

  • 13. [Activation of the antihemophilic globulin A (factor VIII). 2. Effect of ampholine on the course of blood coagulation and the molecular conformation of factor VIII].
    Liebe S
    Z Gesamte Inn Med; 1982 Feb; 37(4):110-6. PubMed ID: 6805144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Coagulography and certain indicators of the blood coagulation system in hemopphilia A].
    Tarasova LN; Koniukhov SG
    Lab Delo; 1976; (1):52-3. PubMed ID: 56495
    [No Abstract]   [Full Text] [Related]  

  • 15. [DDAVP and its effect on factor VIII activity (author's transl)].
    Sikorová J; Vorlová Z
    Cas Lek Cesk; 1981 May; 120(18):553-6. PubMed ID: 6794913
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies on the nature of the circulating anticoagulant directed against antihemophilic factor: with notes on an assay for anthemophilic factor.
    BRECKENRIDGE RT; RATNOFF CD
    Blood; 1962 Aug; 20():137-49. PubMed ID: 13872719
    [No Abstract]   [Full Text] [Related]  

  • 17. Factor VIII half-life and clinical phenotype of severe hemophilia A.
    van Dijk K; van der Bom JG; Lenting PJ; de Groot PG; Mauser-Bunschoten EP; Roosendaal G; Grobbee DE; van den Berg HM
    Haematologica; 2005 Apr; 90(4):494-8. PubMed ID: 15820945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characteristics of the clinical blood coagulation status of heterozygote carriers of hemophilia A].
    Snegireva-Davydenko IB; Pliushch OP; Khametova RN; Shlain VA
    Gematol Transfuziol; 1988 Feb; 33(2):7-10. PubMed ID: 3131184
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.
    Orsini F; Rotschild C; Beurrier P; Faradji A; Goudemand J; Polack B
    Haematologica; 2005 Sep; 90(9):1288-90. PubMed ID: 16154861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.